You are here: Industry Insights > Hoth Therapeutics

News List

Hoth Therapeutics, WuXi STA Sign API and Drug Product Contracts contractpharma
December 10, 2021
WuXi STA to provide process development and manufacturing of the API and formulation of drug product for HT-KIT.
Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way prnewswire
December 01, 2021
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment...
Hoth Therapeutics, WuXi STA Ink API and Drug Product Pact ContractPharma
November 10, 2021
Hoth Therapeutics, Inc., a biopharmaceutical company, has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing...
Hoth Therapeutics and UCRI to perform critical studies for HT-006 antibiotic pharmaceutical-technology
March 19, 2021
Hoth Therapeutics and the University of Cincinnati Research Institute (UCRI) in the US have signed a research agreement to conduct critical antimicrobial characterisation studies for the streamlined development of the antibiotic HT-006.
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment prnewswire
January 04, 2021
Hoth Therapeutics, Inc., a biopharmaceutical company, announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and Dermatological Therapy Pipeline prnewswire
August 20, 2020
Hoth Therapeutics, Inc., a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile testing device as well as its dermatological therapy pipeline.
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment prnewswire
July 01, 2020
Hoth Therapeutics, Inc., a biopharmaceutical company, announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.
Hoth Therapeutics announces agreement to joint development for a self-assembling vaccine (SAV) for the potential prevention of coronavirus pharmaceutical-business-review
March 27, 2020
Hoth Therapeutics has reached an agreement with Voltron Therapeutics to form a joint venture entity, to be named HaloVax, to commence preclinical studies.
Hoth Therapeutics forms JV to develop Covid-19 vaccine pharmaceutical-technology
March 25, 2020
Hoth Therapeutics has collaborated with Voltron Therapeutics to establish a joint venture (JV), HaloVax, for preclinical studies of vaccine candidates against Covid-19.
Hoth Therapeutics to Begin Production of BioLexa Therapeutic americanpharmaceuticalreview
June 13, 2019
Hoth Therapeutics has signed contracts with providers for production of their BioLexa therapeutic, in preparation for upcoming toxicology and clinical studies.